Last reviewed · How we verify
Fumaric acid esters treatment group
At a glance
| Generic name | Fumaric acid esters treatment group |
|---|---|
| Also known as | Fumaderm |
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment (PHASE3)
- Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED) (PHASE3)
- The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis (PHASE4)
- Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fumaric acid esters treatment group CI brief — competitive landscape report
- Fumaric acid esters treatment group updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI